Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
triazole |
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
D01AC18
|
| gptkbp:brand |
gptkb:Jublia
|
| gptkbp:CASNumber |
164650-44-6
|
| gptkbp:chemicalClass |
azole antifungal
|
| gptkbp:discoveredBy |
gptkb:Kaken_Pharmaceutical
|
| gptkbp:eliminationHalfLife |
29.9 hours
|
| gptkbp:form |
10% topical solution
|
| gptkbp:hasMolecularFormula |
C18H22F2N4O
|
| gptkbp:hasSMILES |
CC1=NN(C2=CC=CC=C2N1)C3=CC(=C(C=C3)F)COCCN
|
| https://www.w3.org/2000/01/rdf-schema#label |
efinaconazole
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits ergosterol synthesis
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
95.8%
|
| gptkbp:PubChem_CID |
11370610
CHEMBL2105756 |
| gptkbp:routeOfAdministration |
topical
|
| gptkbp:sideEffect |
application site dermatitis
blistering ingrown toenail pain at application site |
| gptkbp:UNII |
6Z1Y2V4S4T
|
| gptkbp:usedFor |
treatment of onychomycosis
|
| gptkbp:bfsParent |
gptkb:Jublia
gptkb:MK-0518 |
| gptkbp:bfsLayer |
7
|